Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03554083
Title Vemurafenib, Cobimetinib, and Atezolizumab in Treating Participants With High-Risk Stage III Melanoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Mayo Clinic
Indications

melanoma

Therapies

Atezolizumab + Cobimetinib

Atezolizumab + Cobimetinib + Vemurafenib

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.